Department of Basic Pharmaceutical Sciences, Faculty of Pharmacy, Cukurova University, Adana, Turkey.
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ataturk University, Erzurum, Turkey.
Bioorg Chem. 2022 Jul;124:105822. doi: 10.1016/j.bioorg.2022.105822. Epub 2022 Apr 21.
The research in selective monoamine oxidases (MAO-A and MAO-B) inhibitors has been increased due to their therapeutic value for neurodegenerative diseases. In this study, 4-((2-(aryl)-4-oxoquinazolin-3(4H)-yl)amino)benzenesulfonamides were synthesized and their MAOs inhibition potentials were investigated applying in vitro fluorometric technique. The most potent compounds 7 and 8 against MAO-A had IC values of 0.058 ± 0.002 and 0.094 ± 0.003 µM, respectively, while the reference moclobemide had an IC value of 6.061 µM. Compounds 7 (>1724 times) and 8 (>1063 times) more selective and reversible inhibitors of MAO-A rather than MAO-B. Toxicity studies of 7 (IC = 210.23 µM) and 8 (IC = 259.27 µM) showed that compounds can be considered as non-toxic towards SH-SY5Y cell line at their effective concentrations against MAO-A. In silico docking simulations successfully explained the observed activities and also highlighted structural water molecules to play a key role in the ligand-enzyme interactions. Calculated molecular descriptors are also obeying Lipinski's rule of five and brain/blood partition coefficients, a critical parameter in neurodegenerative diseases. These reversible inhibitors can have considerable advantages compared to irreversible inhibitors which may possess serious pharmacological side effects.
由于选择性单胺氧化酶(MAO-A 和 MAO-B)抑制剂在神经退行性疾病中的治疗价值,对其的研究有所增加。在这项研究中,合成了 4-((2-(芳基)-4-氧代喹唑啉-3(4H)-基)氨基)苯磺酰胺,并应用体外荧光技术研究了它们对 MAO 的抑制潜力。对 MAO-A 抑制作用最强的化合物 7 和 8 的 IC 值分别为 0.058 ± 0.002 和 0.094 ± 0.003 μM,而参考药物吗氯贝胺的 IC 值为 6.061 μM。化合物 7(>1724 倍)和 8(>1063 倍)对 MAO-A 的选择性和可逆性均高于 MAO-B。化合物 7(IC = 210.23 μM)和 8(IC = 259.27 μM)的毒性研究表明,在有效浓度下,化合物对 SH-SY5Y 细胞系无毒性。基于配体-酶相互作用,计算机对接模拟成功解释了观察到的活性,同时还强调了结构水分子的关键作用。计算出的分子描述符也符合 Lipinski 的五规则和脑/血分配系数,这是神经退行性疾病的一个关键参数。与可能具有严重药理副作用的不可逆抑制剂相比,这些可逆抑制剂具有相当大的优势。